
1. j infect dis. 2013 mar 1;207(5):740-8. doi: 10.1093/infdis/jis750. epub 2012 dec 
7.

safety efficacy dolutegravir treatment-experienced subjects with
raltegravir-resistant hiv type 1 infection: 24-week results viking study.

eron jj(1), clotet b, durant j, katlama c, kumar p, lazzarin a, poizot-martin i, 
richmond g, soriano v, ait-khaled m, fujiwara t, huang j, min s, vavro c, yeo j; 
viking study group.

collaborators: walmsley sl, cox j, reynes j, morlat p, vittecoq d, livrozet jm,
fernández pv, gatell jm, dejesus e, devente j, lalezari jp, mccurdy lh, sloan la,
young b, lamarca a, hawkins t.

author information: 
(1)infectious diseases division, school medicine, university north
carolina, chapel hill, nc 27599-7215, usa. jeron@med.unc.edu

background: dolutegravir (dtg; s/gsk1349572), human immunodeficiency virus type
1 (hiv-1) integrase inhibitor, limited cross-resistance raltegravir (ral) 
and elvitegravir vitro. phase iib study assessed activity dtg in
hiv-1-infected subjects genotypic evidence ral resistance.
methods: subjects received dtg 50 mg daily (cohort i) 50 mg twice daily
(cohort ii) continuing failing regimen (without ral) day 10,
after background regimen optimized, feasible, cohort i,
and least 1 fully active drug mandated cohort ii. primary efficacy
end point proportion subjects day 11 plasma hiv-1 rna
load decreased ≥0.7 log(10) copies/ml baseline <400 copies/ml.
results: rapid antiviral response observed. subjects achieved the
primary end point cohort ii (23 24 [96%]), compared cohort (21 27
[78%]) day 11. week 24, 41% 75% subjects hiv-1 rna load of
<50 copies/ml cohorts ii, respectively. integrase genotypic
evolution uncommon. dolutegravir good, similar safety profile each
dosing regimen.
conclusion: dolutegravir 50 mg twice daily optimized background provided 
greater durable benefit once-daily regimen. data 
first clinical demonstration activity integrase inhibitor in
subjects hiv-1 resistant ral.

doi: 10.1093/infdis/jis750 
pmcid: pmc3563307
pmid: 23225901  [indexed medline]

